gms | German Medical Science

GMS Hygiene and Infection Control

Deutsche Gesellschaft für Krankenhaushygiene (DGKH)

ISSN 2196-5226

In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii

In-vitro-Synergismus von Kombinationen von Colistin mit ausgewählten Antibiotika gegen Colistin-resistente Acinetobacter baumannii

Research Article

Suche in Medline nach

  • corresponding author Duygu Percin - Department of Microbiology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
  • Selcan Akyol - Department of Microbiology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
  • Gamze Kalin - Department of Infectious Diseases and Clinical Microbiology, Yozgat State Hospital, Yozgat, Turkey

GMS Hyg Infect Control 2014;9(2):Doc14

doi: 10.3205/dgkh000234, urn:nbn:de:0183-dgkh0002345

Veröffentlicht: 19. August 2014

© 2014 Percin et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Aim: The in vitro activity of colistin in combination with sulbactam, netilmicin, and vancomycin against colistin-resistant A. baumannii strains was investigated. Furthermore, the clonal relationship of the strains was analyzed.

Methods: Clonal relationship was investigated using rep-PCR. To screen for synergysm, the fractional inhibitory concentration index (FICI) was calculated using checkerboard assay. The killing kinetics of the combination of colistin with vancomycin was assessed using time-kill assay.

Results: Three different clones were found among 10 clinical isolates of colistin-resistant A. baumannii strains. Thereof, 8 strains were susceptible to netilmicin. Synergistic interaction was detected in 1 strain with the combination of colistin-netilmicin, in 5 strains with colistin-sulbactam, and in 9 strains with colistin-vancomycin. None of combinations had antagonistic activity. Colistin-vancomycin combination resulted in rapid bactericidal activity.

Conclusion: These results show a distinct in vitro synergism between colistin and vancomycin, which might be useful to treat infection with multiple-resistant strains, prevent emergence of resistant strains, and to lower doses for both antibiotics to be used.

Keywords: Acinetobacter baumannii, colistin resistance, fractional inhibitory concentration index (FICI), time-kill assay, synergism, vancomycin, sulbactam, netilmicin


Ziel: Die Kombination von Colistin mit Sulbactam, Netilmicin und Vancomycin wurde in vitro gegen Colistin-resistente A. baumannii-Stämme untersucht und die klonale Verwandtschaft der Stämme analysiert.

Methoden: Die klonale Verwandtschaft wurde mittels rep-PCR untersucht. Der Fractional Inhibitory Concentration Index (FICI) Bruch wurde mit dem Checkerboard-Assay berechnet. Die Abtötungskinetik Colistin-Vancomycin-Kombination wurde mit dem Zeit-Kill-Assay ermittelt.

Ergebnisse: Es wurden 3 verschiedene Klone identifiziert. Alle Isolate waren resistent gegen Colistin, 8 Stämme waren empfindlich gegen Netilmicin. Eine synergistische Wechselwirkung wurde für einen Stamm mit der Kombination Colistin-Netilmicin, für 5 Stämme mit der Kombination Colistin-Sulbactam und für 9 Stämme mit der Kombination Colistin-Vancomycin festgestellt. Bei keiner Kombination trat Antagonismus auf. Die Kombination von Colistin mit Vancomycin ergab eine rasche bakterizide Aktivität.

Fazit: Die In-vitro-Ergebnisse zeigen einen Synergismus für die Kombination von Colistin mit Vancomycin. Damit ist die Möglichkeit gegeben, Infektionen durch multipel-resistente Erreger zu behandeln und der Entstehung resistenter Stämme entgegen zu wirken. Zugleich kann die Dosis für beide Antibiotika gesenkt werden.

Schlüsselwörter: Acinetobacter baumannii, Colistinresistenz, Fractional Inhibitory Concentration Index (FICI), Time-kill Assay, Synergismus, Vancomycin, Sulbactam, Netilmicin


Acinetobacter baumannii is a Gram-negative opportunistic pathogen and one of the leading causes of hospital acquired infections such as septicemia, pneumonia, bacteremia, and urinary tract infections. In recent years, treatment of infections caused by Acinetobacter spp. has become increasingly difficult due to the spread of multidrug-resistant (MDR) strains. For these strains, colistin, an old polimyxin antibiotic, frequently is the only remaining therapeutic option. Nevertheless, colistin-resistant A. baumannii strains have been reported recently [1], [2], [3].

Colistin is a cationic antibiotic, which is bactericidal for Gram-negative bacteria, interacting with lipid A causing disarrangement of the outer membrane [4]. Colistin resistance amongst A. baumanii can occur by two mechanisms: lipopolysaccharide loss or modification of lipid A [5], [6], [7]. Because of the difficulties in the treatment of MDR A. baumannii infections, clinicians have been forced to use combination therapy to achieve synergistic activity. Some studies have demonstrated that colistin combined with rifampin, minocycline, ceftazidime, imipenem, azithromycin can be effective against MDR A. baumannii [8], [9], [10].

In the present study, we investigated the in vitro activity of colistin in combination with sulbactam, netilmicin, and vancomycin against clinical colistin-resistant A. baumannii strains.

Materials and methods

Bacterial isolates

Ten colistin-resistant A. baumannii strains isolated from different patients hospitalized in intensive care units (ICU) were used. Thereof, 5 were isolated from endothracheal aspirates, 2 from bronchoalveolar lavage, and 1 from blood, wound, and pleural fluid each. Identification and antibiotic susceptibility were performed using BD Phoenix Automated Microbiology System (Becton Dickinson, NJ, USA). Antimicrobial susceptibilities against colistin, sulbactam, netilmicin and vancomycin were investigated using microdilution method [11]. The clonal relationship of strains was explored using rep-PCR (DiversiLab, bioMérieux, France).

Checkerboard assay

Antibiotic interactions were determined using checkerboard assay as previously described [12]. The concentrations tested for colistin were 2–1,024 µg/ml; for sulbactam 2–128 µg/ml; for netilmicin 0.25–16 µg/ml, and for vancomycin 8–512 µg/ml. Microbroth dilution plates were inoculated with each A. baumannii isolate to yield ~5x105 CFU/ml in a 200 µl final volume and incubated overnight at 35°C.

The fractional inhibitory concentration index (FICI) was calculated for each combination using the following formula: FICA+FICB=FICI, where FICA=MIC of drug A in combination/MIC of drug A alone, and FICB=MIC of drug B in combination/MIC of drug B alone. The FICI was interpreted as follow: synergism = FICI≤0.5; indifference = 0.5<FICI≤4; antagonism = FICI>4 [13].

Time-killing assays

Tubes containing Mueller-Hinton broth (Oxoid, UK) supplemented with the respective antibiotics were inoculated with A. baumannii isolates to density of ~5x105 CFU/ml in a final volume of 5 ml and incubated at 37°C. The killing kinetics of the colistin vancomycin combination was assessed against each of the isolates using standard time-killing assay and viable bacterial counts. The final concentration of colistin and vancomycin were 1 µg/ml, and 20 µg/ml respectively, to simulate the minimal steady-state concentrations achieved with standard dosing regimens of colistin methanesulfonate (1,000,000 IU of colistin) and continuously infused vancomycin. Aliquots were removed at time 0, 3, 6 and 24 h post incubation, serially diluted in saline for determination of viable counts. Diluted samples (100 µl) were plated on blood agar plates and colonies were counted after overnight incubation. Bactericidal activity was determined as 3 log10 CFU/ml reduction in the colony count relative to the initial inoculum [14].


Clonal relationship

The rep-PCR analysis showed a clonal relationship among the isolates. Six isolates were identified in A clone, 3 isolates in B clone and 1 isolates in C clone (Figure 1 [Fig. 1]).

Antimicrobial susceptibility results

The MIC50, MIC90, and MIC ranges of the isolates are presented in Table 1 [Tab. 1]. According to the CLSI breakpoints [15] for Acinetobacter spp., all isolates were resistant to colistin and 8 strains were susceptible to netilmicin.

Checkerboard assay

Checkerboard analysis was performed with all antimicrobials in combination with colistin. Synergistic interaction was detected in one strain with the combination of colistin-netilmicin, in 5 strains with colistin-sulbactam, and in 9 strains with colistin-vancomycin (Table 2 [Tab. 2]). None of combinations showed antagonistic activity.

Time-killing assays

Time kill assay was performed for the combination of colistin with vancomycin, since this combination showed the highest synergistic in the checkerboard assay and resulted in rapid bactericidal activity. Reduction of 3 log10 CFU/ml in the colony count was seen after 3 h of incubation for 8 isolates and after 6 h of incubation for 2 isolates. After 24 h of incubation, no regrowth did occur (Table 3 [Tab. 3]).


A. baumannii has emerged as an important nosocomial pathogen, especially in ICUs. This organism develops resistance to a variety of antimicrobial agents like broad-spectrum beta-lactams, aminoglycosides, fluoroquinolones and carbapenems [16]. MDR A. baumannii is also endemic in our ICUs and the causative pathogen of critical nosocomial infections with high mortality rate. Carbapenem resistance of A. baumannii doubled from 2000 to 2009 in our hospital [17].

The spread of MDR A. baumannii has been forcing researchers to find new molecules as little choice for treatment remains. Therefore, the use of quite old antimicrobial drugs is reconsidered again. Colistin is an example of a drug that has good activity against A. baumannii and has fallen out of use because of toxicity, but is reemerging now [18], [19]. Nevertheless, there is a risk of emergence of colistin-resistant A. baumannii strains during colistin treatment, if monotherapy is administered [20]. Colistin-resistant clinical isolates have already been reported [1], [2], [3]. For this reason, a combination of colistin with other antimicrobial agents could be more rational.

In the present study we investigated synergistic activities of colistin combined with sulbactam and netilmicin, which are in clinical use today, and with vancomycin, which is not routinely used against Gram-negative organisms, but showed proven synergistic activity on A. baumannii strains [18]. Kempf et al. [20] demonstrated synergistic activity of colistin combination with sulbactam and found that colistin MIC decreased from 32 µg/ml to 4 µg/ml and the sulbactam MIC decreased from 2 µg/ml to 0.5 µg/ml. Gordon et al. [18] tested 34 clinical isolates having vancomycin MICs of >256 µg/ml. The addition of 0.5 µg/ml of colistin reduced the vancomycin MIC in all cases (range 0.0016 > to 48 µg/ml) and the combination of vancomycin with colistin also resulted in rapid bactericidal activity.

The highest synergistic activity was determined in combination of colistin with vancomycin and rapid bactericidal activity was observed in this study. Nephrotoxicity is a reported side effect of both drugs that should be taken into account for clinical use. However, Kalin et al. [19] evaluated concominant antibiotic use, and there was no difference in nephrotoxicity between the patients who received concominant glycopeptide antibiotic and the patients who did not.

In conclusion, our results present a distinct in vitro synergism between colistin and vancomycin. This combination may be useful in the treatment of MDR A. baumannii infections. Moreover, it may help to prevent emergence of resistant strains, to lower doses for both antibiotics to be used, and to prevent nephrotoxicity. Further in vivo investigations are needed to prove the use of colistin-vancomycin combination therapy for infections of MDR A. baumannii.


Competing interests

The authors declare that they have no competing interests.


Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect. 2006 Apr;12(4):315-21. DOI: 10.1111/j.1469-0691.2005.01351.x Externer Link
Rodriguez CH, Bombicino K, Granados G, Nastro M, Vay C, Famiglietti A. Selection of colistin-resistant Acinetobacter baumannii isolates in postneurosurgical meningitis in an intensive care unit with high presence of heteroresistance to colistin. Diagn Microbiol Infect Dis. 2009 Oct;65(2):188-91. DOI: 10.1016/j.diagmicrobio.2009.05.019 Externer Link
Park YK, Choi JY, Jung SI, Park KH, Lee H, Jung DS, Heo ST, Kim SW, Chang HH, Cheong HS, Chung DR, Peck KR, Song JH, Ko KS. Two distinct clones of carbapenem-resistant Acinetobacter baumannii isolates from Korean hospitals. Diagn Microbiol Infect Dis. 2009 Aug;64(4):389-95. DOI: 10.1016/j.diagmicrobio.2009.03.029 Externer Link
Hancock RE. Peptide antibiotics. Lancet. 1997 Feb 8;349(9049):418-22. DOI: 10.1016/S0140-6736(97)80051-7 Externer Link
Arroyo LA, Herrera CM, Fernandez L, Hankins JV, Trent MS, Hancock RE. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother. 2011 Aug;55(8):3743-51. DOI: 10.1128/AAC.00256-11 Externer Link
Beceiro A, Llobet E, Aranda J, Bengoechea JA, Doumith M, Hornsey M, Dhanji H, Chart H, Bou G, Livermore DM, Woodford N. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother. 2011 Jul;55(7):3370-9. DOI: 10.1128/AAC.00079-11 Externer Link
Moffatt JH, Harper M, Harrison P, Hale JD, Vinogradov E, Seemann T, Henry R, Crane B, St Michael F, Cox AD, Adler B, Nation RL, Li J, Boyce JD. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010 Dec;54(12):4971-7. DOI: 10.1128/AAC.00834-10 Externer Link
Tan TY, Ng LS, Tan E, Huang G. In vitro effect of minocycline and colistin combinations on imipenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2007 Aug;60(2):421-3. DOI: 10.1093/jac/dkm178 Externer Link
Tripodi MF, Durante-Mangoni E, Fortunato R, Utili R, Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents. 2007 Dec;30(6):537-40. DOI: 10.1016/j.ijantimicag.2007.07.007 Externer Link
Wareham DW, Bean DC. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob. 2006;5:10. DOI: 10.1186/1476-0711-5-10 Externer Link
Clinical and Laboratory Standard Institute. Methods for Dilution Antimicrobial Disk Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard. Eighth Edition. CLSI document M07-A8. Wayne, PA: Clinical and Laboratory Standard Institute; 2009.
Eliopoulos GM, Moellering RC. Antimicrobial combinations. In: Lorian V, editor. Antibiotics in laboratory medicine. 3rd ed. Baltimore, MD: Williams & Wilkins; 1991. p. 432-92.
Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006 Mar;57(3):573-6. DOI: 10.1093/jac/dki477 Externer Link
Pankuch GA, Jacobs MR, Appelbaum PC. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob Agents Chemother. 1994 Sep;38(9):2065-72. DOI: 10.1128/AAC.38.9.2065 Externer Link
Clinical and Laboratory Standard Institute. Performance Standards for Antimicrobial Susceptibility Testing. Twenty-First Informational Supplement. CLSI document M100-S21. Wayne, PA: Clinical and Laboratory Standards Institute; 2011.
Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y. Multidrug-resistant Acinetobacter baumannii. Emerging Infect Dis. 2005 Jan;11(1):22-9. DOI: 10.3201/eid1101.040001 Externer Link
Alp E, Kiran B, Altun D, Kalin G, Coskun R, Sungur M, Akin A, Percin D, Doganay M. Changing pattern of antibiotic susceptibility in intensive care units: ten years experience of a university hospital. Anaerobe. 2011 Dec;17(6):422-5. DOI: 10.1016/j.anaerobe.2011.04.017 Externer Link
Gordon NC, Png K, Wareham DW. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2010 Dec;54(12):5316-22. DOI: 10.1128/AAC.00922-10 Externer Link
Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M. Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother. 2012 Dec;18(6):872-7. DOI: 10.1007/s10156-012-0430-7 Externer Link
Kempf M, Djouhri-Bouktab L, Brunel JM, Raoult D, Rolain JM. Synergistic activity of sulbactam combined with colistin against colistin-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2012 Feb;39(2):180-1. DOI: 10.1016/j.ijantimicag.2011.10.001 Externer Link